- Home
- MYO vs MRSN Comparison
MYO vs MRSN Comparison
Compare MYO & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- MRSN
- Stock Information
- Founded
- MYO 2004
- MRSN 2001
- Country
- MYO United States
- MRSN United States
- Employees
- MYO N/A
- MRSN N/A
- Industry
- MYO Industrial Specialties
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- MRSN Health Care
- Exchange
- MYO Nasdaq
- MRSN Nasdaq
- Market Cap
- MYO 44.6M
- MRSN 37.0M
- IPO Year
- MYO 2017
- MRSN 2017
- Fundamental
- Price
- MYO $0.96
- MRSN $7.01
- Analyst Decision
- MYO Strong Buy
- MRSN Strong Buy
- Analyst Count
- MYO 3
- MRSN 3
- Target Price
- MYO $8.17
- MRSN $33.00
- AVG Volume (30 Days)
- MYO 2.1M
- MRSN 92.7K
- Earning Date
- MYO 11-05-2025
- MRSN 08-13-2025
- Dividend Yield
- MYO N/A
- MRSN N/A
- EPS Growth
- MYO N/A
- MRSN N/A
- EPS
- MYO N/A
- MRSN N/A
- Revenue
- MYO $40,760,091.00
- MRSN $34,769,000.00
- Revenue This Year
- MYO $25.69
- MRSN N/A
- Revenue Next Year
- MYO $23.52
- MRSN N/A
- P/E Ratio
- MYO N/A
- MRSN N/A
- Revenue Growth
- MYO 93.08
- MRSN 16.14
- 52 Week Low
- MYO $0.92
- MRSN $5.21
- 52 Week High
- MYO $7.17
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- MYO 24.94
- MRSN 44.55
- Support Level
- MYO $0.96
- MRSN $6.63
- Resistance Level
- MYO $1.17
- MRSN $7.25
- Average True Range (ATR)
- MYO 0.07
- MRSN 0.47
- MACD
- MYO 0.03
- MRSN -0.03
- Stochastic Oscillator
- MYO 5.82
- MRSN 19.09
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.